CoChat

Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia

Open access
Karwatowska-Prokopczuk, Ewa, Tardif, Jean-Claude, Gaudet, Daniel, Ballantyne, Christie M., Shapiro, Michael D., Moriarty, Patrick M., Baum, Seth J., Amour, Eric St, Alexander, Veronica J., Xia, Shuting, Otvos, James D., Witztum, Joseph L., Tsimikas, Sotirios · 2022 · Journal of Clinical Lipidology
Cited by 51

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Olezarsen is a hepatocyte-targeted, GalNAc-modified antisense oligonucleotide that decreases plasma levels of apolipoprotein C-III (apoC-III) and triglyceride-rich lipoproteins (TRLs). OBJECTIVE: To define the effect of olezarsen on NMR-derived lipoprotein particle size and concentration. METHODS: Patients (n=114) with or at risk for atherosclerotic cardiovascular disease and fasting triglycerides ≥200 and <500 mg/dL received olezarsen (10 or 50 mg every 4 weeks, 15 mg every 2 weeks, or 10 mg every week) or saline placebo subcutaneously for 6-12 months. NMR LipoProfile® analysis was performed in frozen EDTA plasma samples collected at baseline and at the primary analysis timepoint (PAT) at 6 months. RESULTS: A dose-dependent relationship was generally noted with increasing cumulative doses of olezarsen in TRL particle (TRLP), LDL particle (LDL-P) and HDL (HDL-P) particle concentrations. In the 50 mg every 4 weeks dose, compared to placebo, olezarsen resulted in a significant reduction in total TRL-P (51%, P<0.0001) with largest reductions in large-size (68%, P<0.0001) and medium-size (63%, P<0.0001) TRL-P. Total LDL-P concentration was not changed, but large LDL-P increased by 186% (p=0.0034), and small LDL-P decreased by 39% (p=0.0713). Total HDL-P concentration increased by 15% (P=0.0006), driven primarily by a 32% increase in small HDL subspecies (diameters <8.3 nm) (P=0.0008). CONCLUSION: Olezarsen results in favorable changes in lipoprotein concentration and particle size, primarily manifested by reduction in TRLs, remodeling to larger LDL particles, and increase in small HDL-P. These findings suggest that apoC-III inhibition improves the overall atherogenic risk profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacl.2022.06.005

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 51

Metadata

Authors
Karwatowska-Prokopczuk, E., Tardif, J.-C., Gaudet, D., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Amour, E. S., Alexander, V. J., Xia, S., Otvos, J. D., Witztum, J. L., & Tsimikas, S.
Venue
Journal of Clinical Lipidology
Publisher
Elsevier BV
Published
2022-09
Volume
16
Issue
5
Pages
617-625
ISSN
  • 1876-4789 (ISSN-L)
  • 1933-2874
OpenAlex
W4283319095
Cited by
51
References
19
FWCI
8.27
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. https://app.cochat.ai/papers/10.1016/j.jacl.2022.06.005
The paper
Karwatowska-Prokopczuk, E., Tardif, J.-C., Gaudet, D., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Amour, E. S., Alexander, V. J., Xia, S., Otvos, J. D., Witztum, J. L., & Tsimikas, S. (2022). Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2022.06.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.